Ophthalmology-focused medical device supplier VisionX has secured over $100 million for its Series B round of financing, per a company statement on Thursday.
The round attracted two new investors – Temasek Holdings and Lake Bleu Capital.
Return backers Sequoia Capital China, Green Pine Capital Partners and investment firms – Sherpa Healthcare Partners, 3H Health, Highlight Capital – joined the round.
VisionX expects to deploy the capital for talent recruitment, R&D and commercialisation of new candidates.
VisionX’s therapy areas target prevention of myopia in teenagers, eyesight correction for adults, ocular surface diseases, optometry diagnostics therapy and equipment, vision nursing and eyesight care products.
Earlier this year, VisionX had raised over 100 million yuan ($15 million) in its pre-Series B round from Sequoia Capital China, Green Pine Capital Partners, Sherpa Healthcare Partners, 3H Health, Highlight Capital, Yuanbio Venture Capital, and Fosun Capital.